Marjolijn Duijm-de Carpentier Selected Research

2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- one

1/2021

Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marjolijn Duijm-de Carpentier Research Topics

Disease

7	Breast Neoplasms (Breast Cancer) 01/2021 - 03/2015
2	Neoplasms (Cancer) 01/2021 - 01/2021

Drug/Important Bio-Agent (IBA)

5	Hormones (Hormone)IBA 01/2021 - 01/2018
3	Letrozole (Femara)FDA LinkGeneric 01/2021 - 01/2018
1	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Aromatase InhibitorsIBA 01/2018
1	Tamoxifen FDA LinkGeneric 03/2015
1	exemestane (Aromasin)FDA Link 03/2015

Therapy/Procedure

4	Therapeutics 01/2021 - 01/2018
1	Neoadjuvant Therapy 01/2021